Trevi Therapeutics Inc [TRVI] stock is trading at $6.75, up 7.31%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TRVI shares have gain 56.98% over the last week, with a monthly amount glided 66.67%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Trevi Therapeutics Inc [NASDAQ: TRVI] stock has seen the most recent analyst activity on March 10, 2025, when Raymond James upgraded its rating to a Strong Buy and also boosted its price target to $29 from $9. Previously, Needham reaffirmed its Buy rating on March 10, 2025, and elevated its price target to $25. On December 12, 2024, H.C. Wainwright reiterated its Buy rating and revised its price target to $7.50 on the stock. Raymond James initiated its recommendation with a Outperform and recommended $9 as its price target on August 30, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on August 30, 2024, and assigned it a price target of $6. In a note dated June 13, 2024, Rodman & Renshaw initiated an Buy rating and provided a target price of $7 on this stock.
Trevi Therapeutics Inc [TRVI] stock has fluctuated between $2.30 and $7.39 over the past year. Currently, Wall Street analysts expect the stock to reach $6 within the next 12 months. Trevi Therapeutics Inc [NASDAQ: TRVI] shares were valued at $6.75 at the most recent close of the market. An investor can expect a potential drop of -11.11% based on the average TRVI price forecast.
Analyzing the TRVI fundamentals
Gross Profit Margin for this corporation currently stands at 0.39% with Operating Profit Margin at -273.95%, Pretax Profit Margin comes in at -251.97%, and Net Profit Margin reading is -251.8%. To continue investigating profitability, this company’s Return on Assets is posted at -0.64, Equity is -0.63 and Total Capital is -0.81. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.42 points at the first support level, and at 6.10 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.93, and for the 2nd resistance point, it is at 7.11.
Ratios To Look Out For
For context, Trevi Therapeutics Inc’s Current Ratio is 7.38. Also, the Quick Ratio is 7.38, while the Cash Ratio stands at 1.76.
Transactions by insiders
Recent insider trading involved Simon Farrell, Chief Commercial Officer, that happened on Mar 10 ’25 when 81313.0 shares were sold. Officer, Simon Farrell completed a deal on Mar 10 ’25 to buy 81313.0 shares. Meanwhile, President & CEO GOOD JENNIFER L sold 4219.0 shares on Sep 06 ’24.
